The in vitro and in vivo toicities (16, 28) . However, a large number of undesirable effects, both immediate (e.g., fever, chills, and hypotension) and delayed (especially altered renal function), limit its usefulness (2, 33), and toxicity, more or less severe, is almost unavoidable during systemic treatment. Therefore, a number of new antifungal drugs, particularly azoles, which are well tolerated and effective in some systemic mycoses, have been developed. However, the treatment of certain infections remains difficult, particularly in neutropenic patients with invasive candidiasis (6, 36) or aspergillosis (5, 14) or in AIDS patients with cryptococcosis (19).
Different biological properties contribute to the value of polyene macrolide antifungal agents: a broad antifungal spectrum, including most clinically relevant yeast-like and ifiamentous fungi; an exceptionally low rate of acquired resistance; and a definite fungicidal effect. Amphotericin B (AmB), the only polyene to be administered parenteraly, remains the treatment of choice for most systemic fungal infections (16, 28) . However, a large number of undesirable effects, both immediate (e.g., fever, chills, and hypotension) and delayed (especially altered renal function), limit its usefulness (2, 33) , and toxicity, more or less severe, is almost unavoidable during systemic treatment. Therefore, a number of new antifungal drugs, particularly azoles, which are well tolerated and effective in some systemic mycoses, have been developed. However, the treatment of certain infections remains difficult, particularly in neutropenic patients with invasive candidiasis (6, 36) or aspergillosis (5, 14) or in AIDS patients with cryptococcosis (19) .
Different approaches have been used to increase the therapeutic index of AmB, e.g., incorporating the drug into liposomes or modifying its structure with the aim of lowering the level of toxicity. Liposomal AmB has proved effective experimentally (26, 34) and in patients (24, 25, 32) , but its use remains limited by cost and problems of long-term availability. Two water-soluble AmB esters, AmB methylester and N-D-ornithyl AmB methylester, have been studied (12, (10, 27) . Using a new synthetic process, we developed several Amadori derivatives of AmB which are highly hydrosoluble, and the N-methyl glucamine salt of 1-deoxy-1-amino-4,6-O-benzylidene-D-fructosyl-AmB (MS-8209) was selected for further evaluation. This compound has shown in vitro activity against human immunodeficiency virus type 1 (4) .
In this paper, we report the experimental toxicity and activity of MS-8209. Toxicity was evaluated in vitro against renal tubular cells in primary culture and in vivo in noninfected mice by determining the 50%o lethal dose (LD5).
Antifungal activity was assessed in vitro against Candida albicans and Cryptococcus neofonnans and in vivo in different murine models of systemic opportunistic fungal infections: candidiasis, cryptococcosis, and pulmonary aspergillosis. The Preparation of solutions. AmB was dissolved in dimethyl sulfoxide at a concentration of 30 mg/ml and then further diluted in phosphate-buffered saline (PBS) (pH 7.4). D-AmB was dissolved in 5% glucose at a concentration of 5 mg/ml and further diluted in PBS.
MS-8209 was dissolved in 5% glucose at a concentration of 10 mg/ml and further diluted in PBS.
In vitro studies. (i) toxicity against renal tubular cells in primary culture. Kidneys were excised under anesthesia from male New Zealand rabbits (Evic Ceba, Blanquefort, France) (800 to 1,000 g), and primary confluent monolayers were grown from proximal tubule fragments in serum-free medium, as previously reported (18) . Serum-free medium, referred to as culture medium, consisted of a 1:1 (vol/vol) mixture of Ham's F-12 and Dulbecco's modified Eagle's medium supplemented with 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 21.5 mM HCO3, 1 mM sodium pyruvate, 4 mM L-glutamine, 10 ml of a 100x nonessential amino acid mixture per liter, 50 U of penicillin per ml, 50 ,ug of streptomycin per ml, 100 nM sodium selenite, 35 mg of transferrin per liter, 5 mg of insulin per liter, 100 nM hydrocortisone, and 20 ,uM ethanolamine. The cultures became confluent in 5 to 6 days. All experiments reported were carried out on day 7.
Culture medium was changed the day before experiments. On day 7, cells grown to confluence were incubated with fresh culture medium containing the appropriate concentrations of AmB or MS-8209 for 1 h. The final concentration of dimethyl sulfoxide in the supernatants of treated wells was less than 0.14%.
Pi uptake was chosen as the marker of early tubular toxicity, as described previously (18) . AmB or MS-8209 was removed after 1 h of incubation by washing, and Pi uptake was measured as reported elsewhere (18) . Briefly, Pi uptake was determined at 37°C in a buffered uptake solution of the following composition (millimoles per liter): NaCl, 137; KCl, 5.4; CaCl2, 1; MgSO4, 1.2; HEPES (pH 7.4), 15. Choline chloride replaced sodium chloride in the sodium-free solution. Cells were washed twice with 0.5 ml of the appropriate ice-cold uptake solution per well and then were incubated for 10 min in the presence of K2H32P04 (0.5 ,Ci/ml) and 0.1 mM unlabeled KH2PO4. We verified previously that Pi uptake increased linearly with time up to 10 min. Uptake was stopped by washing the cells twice with 1 ml of ice-cold buffer (137 mM NaCl, 15 mM HEPES [pH 7.4]) per well. Cells were then solubilized in 0.5% Triton X-100 (250 ,ul per well), and aliquots were counted by liquid scintillation. Radioactive counts in each sample were normalized with respect to the protein content of each well determined according to Bradford's method (1) . Each experimental point was run in triplicate.
The antifungal activities of D-AmB and MS-8209 were investigated in vitro against the C. albicans and C. neoformans strains used in vivo. C. albicans was isolated from a patient's blood culture. C. neoformans serotype A (strain 271) was a gift from J. E. Bennett and had been used previously (9, 21 (ii) Activity in experimental cryptococcosis. Experimental cryptococcosis was induced in DBAI2 mice infected i.v. with 2 x 106 C. neofornans cells, an inoculum responsible for early fatal pneumonia (lethal in 2 days), or in BALB/c mice infected i.v. with 2 x 106 C. neoformans cells, an inoculum leading to delayed meningitis (lethal in 15 days), as previously described (9) . Yeast cells were counted before infectlon, and the precise number of viable cells injected was verified retrospectively by plating on Sabouraud-chloramphenicol agar.
In each experiment, treated and untreated groups (at least eight mice per group) were compared. Cages were monitored at least once daily to evaluate the viabilities of animals. In both models of infection, the treatment was administered i.v. 30 h after infection. A 30-h delay between infection and treatment was chosen because D-AmB at all doses tested was never effective when given later in the model of acute pneumonia. We determined that the maximum tolerated dose of D-AmB was 1.2 mg/kg of body weight in both models (less than 15% mortality due to the drug). Higher doses were toxic, and lower doses were less effective. In the same way, we tested different doses of MS-8209 to determine the maximum tolerated dose and compared the doses with 1.2 mg of D-AmB per kg used as the reference treatment. The doses of MS-8209 that we studied took into account the LD50 of the compound as determined previously in noninfected OF1 mice. For acute pneumonia, DBA/2 mice were treated with a single injection of MS-8209 at 20, 25, or 30 mg/kg. In the meningoencephalitis model, BALB/c mice were treated with a single injection of MS-8209 at 20 or 25 mg/kg 30 h after infection.
The numbers of viable fungi in major organs were determined 2 and 15 days after infection with 2 x 106 C. neoformans cells in DBA/2 mice (acute_pneumonia) and 2, 9, and 15 days after infection with 2 x 10 C. neoformans cells in BALB/c mice (meningoencephalitis). Mice were treated 30 h after infection with the most effective dose of D-AmB or MS-8209 determined according to the survival curves. In each experiment, values were compared with those obtained in mice infected with the same inoculum and left untreated; four mice per group per day were studied. Mice were killed by cervical dislocation, and the CFU were counted after 10-fold dilutions of spleen, lung, and brain tissue homogenates plated in duplicate on Sabouraud-chloramphenicol agar. Colonies were counted after 48 h of incubation at 37°C. The method was sensitive to 2100 CFU/g. VOL. 36, 1992 (iii) Activity in experimental candidiasis. Experimental systemic candidiasis was obtained in male OF1 mice infected i.v. with 2 x 106 C. albicans cells. Yeast cells were counted before infection, and the precise number of viable cells injected was verified retrospectively by plating on Sabouraud-chloramphenicol agar.
In each experiment, treated and untreated groups (at least eight mice per group) were compared. Cages were monitored at least once daily to evaluate the viabilities of animals. Mice were treated 20 h after infection. We determined that the maximum tolerated doses were 0.5 and 15 mg/kg for D-AmB and MS-8209, respectively.
The number of viable fungi in the kidney was determined 2 and 9 days after infection of OF1 mice with 2 x 106 C. albicans cells. OF1 mice were treated 20 h after infection by the most effective dosages as determined from the survival study. In each experiment, values were compared with those obtained in mice infected with the same inoculum and left untreated; five mice per group per day were studied. We used the same procedures as those described for cryptococcosis, and the sensitivity of the method was the same as that indicated above.
(iv) Activity in experimental pulmonary aspeglosis. Pulmonary aspergillosis was induced in OF1 male mice by using Aspergillus fumigatus DMD 401, kindly provided by A. Polak (Basel, Switzerland) and used previously (8, 21) . Cultures were grown on potato glucose agar (Diagnostics Pasteur, Marnes-la-Coquette, France) in sterile 25-ml plastic flasks for 5 days.
Cortisone acetate (Sigma) was suspended in sterile water containing 0.1% Tween 80, and 125 mg in 0.2 ml was injected subcutaneously per kg on days -3 and -1, with day 0 being the day of infection.
OF1 male mice were anesthetized with a mixture of absolute ethanol-chloroform-ether (1:2:3) as described previously (21) . Five-day sporulating cultures of A. fiumigatus grown in 25-ml flasks were used for inoculation. Each mouse was held with its nose in the neck of the culture flask, and spores were mobilized by forcing air with a syringe through the flask. Inhalation time was 1 min. In this model, at least 90% mortality was obtained in untreated mice, with 50% of the deaths observed by day 5. Beyond 20 days, no additional deaths were recorded, and the surviving mice were considered cured.
For the survival study, mice were treated i. of 25 Fg/ml, MS-8209 was atoxic even at 40 ,g/ml, the highest concentration tested (Fig. 1) .
(ii)AntiIungal activity. We observed that both D-AmB and MS-8209 were more active against C. albicans than against C neoformans and that at 10-fold the concentration of D-AmB, MS-8209 exhibited roughly the same effect as D-AmB. At 6 h, 1 p.g of D-AmB per ml and 10 ,ug of MS-8209 decreased the initial C. albicans inoculum by more than 2.5 log, whereas 5 pg of D-AmB per ml and 50 pg of MS-8209 per ml decreased the initial C. neoformans inoculum by 1 log only. The maximum effect of MS-8209 against C. neoformans was achieved at 24 h (Fig. 2) .
In vivo studies. (i) Toxicity. The LD5,s at day S in 7-weekold OF1 uninfected mice were 26 mg/kg for MS-8209 and 2.3 mg/kg for D-AmB. Unlike D-AmB, which caused immediate death following administration of toxic doses, MS-8209 was responsible for delayed mortality until day 5 after treatment (data not shown).
(ii) In vivo antifungal activity in candidiasis. Mice were severely ill with candidiasis at the time of treatment. The maximum tolerated doses of MS-8209 (15 mg/kg) and D-AmB (0.5 mg/kg) were lower in infected than in healthy mice. MS-8209 at 15 mg/kg significantly increased the survival of mice compared with controls and D-AmB-treated mice (P < 0.01) (Fig. 3) . On day 2, CFU counts were significantly lower in the kidneys of mice treated with the optimal dose of D-AmB or MS-8209 than in the kidneys of controls (P < 0.05) ( Table 1) . On day 9, kidney CFU counts were comparable in D-AmBand MS-8209-treated mice. On day 9, kidney CFU counts were significantly lower than those on day 2 in MS-8209-treated mice but not in D-AmB-treated mice. The kidney was sterile in 20% of D-AmB-treated mice compared with 60% of MS-8209-treated mice.
In vivo antifungal activity in cryptococcosis. In mice with acute pneumonia, the maximum tolerated dose of MS-8209 given 30 h after infection was 25 mg/kg. The mean survival times were 30.9 + 18.1 and 25.6 + 15.8 days for MS-8209-and D-AmB-treated mice, respectively, but the difference between these two groups was not significant (Fig. 4A) . In mice with meningoencephalitis, the maximum tolerated dose of MS-8209 given 30 h after infection was 20 mg/kg. MS-8209 was more effective than the maximum tolerated dose of D-AmB (1.2 mg/kg) at increasing the survival time of mice (25.1 + 2.1 and 19.5 + 0.6 days with MS-8209 and AmB, respectively; P < 0.001) (Fig. 4B) .
For pneumonia, on day 2, 18 h after treatment, both drugs were effective in lung but not in brain ( 16 .
In vivo antifungal activity in aspergillosis. MS-8209 and AmB both significantly prolonged the survival of treated animals compared with those in the control group (Fig. 5) (17, 31) and often less effective than AmB in vivo (11, 35) , polyenes are fungicidal. Fungicidal effect has been described previously with other AmB derivatives (29, 30) and with glucan synthase inhibitors, but these last compounds have a narrow spectrum of activity compared with that of polyenes.
Analysis of toxicity and activity data obtained in vitro thus showed that the alteration of AmB's structure which yielded MS-8209 led to a decrease in activity which was balanced by None (control)
6.26 ± 0.59 Significantly different from the value measured on day 2 in MS-8209-treated mice. When a culture was sterile, the value equivalent to the lower sensitivity limit (100 CFU) was used to calculate the mean of CFU counts in the kidney. VOL. 36, 1992 a decrease in toxicity. We therefore tried to elucidate whether MS-8209 had an in vivo advantage over D-AmB, i.e., whether this new compound had a higher therapeutic ratio than D-AmB. As D-AmB is less well tolerated in severely ill patients, we first determined the maximum tolerated doses of MS-8209 and D-AmB in infected mice and then compared the activities of both drugs given at these selected doses. For candidiasis, we chose to treat mice 20 h after infection, when they were severely ill. Earlier administration (8 h after infection) results in the survival of more than 80% of the treated mice monitored for over 3 months, thereby excluding survival as a basis of comparison for different compounds. MS-8209 was more effective than D-AmB at prolonging survival, but when CFU counts in the kidney were considered, the two drugs were comparable. This lack of significance could be due to the small number of animals studied. However, CFU counts decreased significantly from day 2 to day 9 in the kidneys of MS-8209-treated mice, in contrast to what was observed in D-AmB-treated mice. Whether MS-8209 was more efficient than D-AmB at reducing CFU counts in other organs than the kidney was not investigated.
For cryptococcosis, comparison of the maximum tolerated dose of each drug demonstrated that MS-8209 was significantly superior to D-AmB for increasing survival of mice with chronic meningitis and for reducing CFU counts in both acute pneumonia and meningitis models of infection. The difference between the two treatments was more obvious at the later evaluation of CFU counts than on day 2. The most striking effect of MS-8209 was observed in the lungs, which were sterile 2 weeks after therapy in both models. That the maximum effect of MS-8209 was achieved later than day 2 in cryptococcosis as in candidiasis might be due either to a delayed fungicidal effect or to sustained levels of the drug in tissues after administration. Pharmacokinetic studies will provide information to clarify this point. The decrease in CFU counts over time in MS-8209-treated mice confirmed that MS-8209 not only delayed the growth of yeast but was indeed fungicidal in vivo. Although it cannot be ruled out, a carryover effect probably does not account for the observed results: samples were 100-fold diluted for day 2 experiments, and lower CFU counts were measured after 10 days of treatment than after 2 days, whereas local drug levels would be expected to decrease.
Another mechanism allowing late (day 15) clearance of infection could be the stimulation by MS-8209 of the immune system or of cytokine production. Although interactions between polyenes and the immune system are complex, such beneficial immunostimulant effects have been described with AmB and some of its derivatives (23) . The effect of MS-8209 on CFU counts was more impressive in DBA/2 than in BALB/c mice. This might be related to the rapid growth of C. neofornans in DBA/2 mice, which are CS deficient and more sensitive to cryptococcosis than BALB/c mice. An important point is that MS-8209 was highly effective in lung and brain, which are the two main targets of cryptococcal infection in AIDS patients (3, 7) .
Other polyenes have been reported to have a better in vivo efficacy in experimental candidiasis than AmB. This ability was attributed to the better tolerance of high doses (13, 20, 30) , but in experimental cryptococcosis, ornithyl AmB methylester remained less effective than AmB even though it was given at fivefold the AmB dosage (30) . The highest tolerated dose was not determined in this latter study.
For experimental aspergillosis, MS-8209 was as effective as AmB. Since this is a very severe model of infection, the administration of the drug had to be repeated. This was done early in the course of the infection in order to avoid interference between toxicity and lack of efficacy in assigning the cause of death. However, this mode of administration is more representative of preventive than curative treatment, since the first injection was given before spores were inhaled. The similar efficacies of AmB and one of its derivatives in experimental aspergillosis have been described previously (15) .
No toxicity was evident in these short-term experiments. However, given the neurotoxicity reported for other AmB derivatives, a careful evaluation of toxicity under conditions of chronic administration must now be performed before more extensive studies with this new compound are undertaken. However, it has to be stressed that the AmB derivatives that induced neurotoxicity were esterified polyenes. MS-8209 belongs to a new class of AmB derivatives lacking the ester bond that might be involved in the neurotoxic effects.
In conclusion, MS-8209 is a new hydrosoluble AmB derivative which is as effective as or more effective than AmB in the treatment of experimental systemic candidiasis, cryptococcosis, and aspergillosis when both drugs are given at the maximum tolerated doses. The efficacy of MS-8209 in cryptococcosis is of particular interest since at present, cryptococcal meningitis represents a severe infection in AIDS patients for which an optimal therapeutic regimen remains to be determined.
